Ingela Nilsson Remahl MD, PhD, Head of the Headache Center, Karolinska University Hospital.  Sweden, Denmark, Norway and Finland have independently developed their regulations for reimbursing treatment with anti-CGRP monoclonal antibodies, resulting in different levels of access to treatment and inconsistent eligibility criteria.

Ingela Nilsson Remahl MD, PhD, Head of the Headache Center, Karolinska University Hospital. Sweden, Denmark, Norway and Finland have independently developed their regulations for reimbursing treatment with anti-CGRP monoclonal antibodies, resulting in different levels of access to treatment and inconsistent eligibility criteria.

Ingela Nilsson Remahl MD, PhD, Head of the Headache Center, Karolinska University Hospital.&nbsp; Sweden, Denmark, Norway and Finland have independently developed their regulations for reimbursing treatment with anti-CGRP monoclonal antibodies, resulting in different levels of access to treatment and inconsistent eligibility criteria.

Share Nordic Reimbursement Guidelines for aCGRP Treatment - Sweden

Sign up to save your podcasts

Nordic Reimbursement Guidelines for aCGRP Treatment - Sweden

Nordic Reimbursement Guidelines for aCGRP Treatment - Sweden